Company research
Outset Medical, Inc.
CIK 1484612Updated Sep 27, 2026
SecurityOM · NASDAQ · equity
Name history
Home Dialysis Plus, Ltd. · through Feb 25, 2011
OM price & chart
Loading TradingView…
NASDAQ:OM on TradingView ↗About the company
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control - enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.
In the news
Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026 ↗
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Outset Medical, Inc. (NASDAQ: OM) and Encourages Investors with Substantial Losses to Contact the Firm News provided by Edelson Lechtzin LLP Nov 28, 2025, 15:06 ET Share this article Share to X Share this article Share to X NEWTOWN ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
144 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 264,496,000Source | 275,795,000Source | 313,801,000Source | 400,115,000Source |
| Property, Plant and Equipment, NetUSD | 4,670,000Source | 8,133,000Source | 13,273,000Source | 15,876,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 35,006,000Source | 124,014,000Source | 68,509,000Source | 73,222,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 28,329,000Source | 35,619,000Source | 32,980,000Source | 28,070,000Source |
| Inventory, NetUSD | 47,609,000Source | 59,387,000Source | 49,215,000Source | 51,476,000Source |
| Assets, CurrentUSD | 250,883,000Source | 258,221,000Source | 291,219,000Source | 373,645,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,999,000Source | 4,530,000Source | 5,700,000Source | 6,597,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,797,000Source | 3,940,000Source | 5,375,000Source | 6,117,000Source |
| Other Assets, NoncurrentUSD | 317,000Source | 2,172,000Source | 605,000Source | 1,166,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 137,544,000Source | 248,976,000Source | 190,915,000Source | 154,125,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 18,000Source | 53,000Source | 50,000Source | 48,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,171,376,000Source | -1,089,723,000Source | -961,747,000Source | -788,950,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 172,000Source | 42,000Source | 68,000Source | -564,000Source |
| Stockholders' Equity Attributable to ParentUSD | 126,952,000Source | 26,819,000Source | 122,886,000Source | 245,990,000Source |
| Additional Paid in Capital, Common StockUSD | 1,298,138,000Source | 1,116,447,000Source | 1,084,515,000Source | 1,035,456,000Source |
| Liabilities and EquityUSD | 264,496,000Source | 275,795,000Source | 313,801,000Source | 400,115,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 37,630,000Source | 45,378,000Source | 55,323,000Source | 51,949,000Source |
| Operating Lease, Liability, CurrentUSD | 1,739,000Source | 1,799,000Source | 1,593,000Source | 1,318,000Source |
| Accounts Payable, CurrentUSD | 554,000Source | 3,862,000Source | 5,827,000Source | 603,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,271,000Source | 2,684,000Source | 4,482,000Source | 5,576,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 287,500,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 96,237,000Source | 197,375,000Source | 130,113,000Source | 96,336,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 96,237,000Source | 197,375,000Source | 130,113,000Source | 96,336,000Source |
| Short-term InvestmentsUSD | 133,940,000Source | 34,671,000Source | 134,815,000Source | 214,280,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 4,341,000Source | 5,728,000Source | 5,810,000Source | 5,169,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 15,616,000Source | 29,356,000Source | 38,634,000Source | 27,203,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -3,775,000Source | 5,012,000Source | 5,094,000Source | 2,506,000Source |
| Increase (Decrease) in InventoriesUSD | -11,793,000Source | 10,857,000Source | -1,647,000Source | 14,730,000Source |
| Increase (Decrease) in Accounts PayableUSD | -3,293,000Source | -1,948,000Source | 5,312,000Source | -1,281,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -46,327,000Source | -116,303,000Source | -131,373,000Source | -145,729,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -97,684,000Source | 103,938,000Source | 83,026,000Source | -66,295,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 798,000Source | 912,000Source | 3,440,000Source | 8,325,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 55,503,000Source | 67,870,000Source | 43,652,000Source | 72,898,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -88,508,000Source | 55,505,000Source | -4,695,000Source | -139,126,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 71,838,000Source | 76,533,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 15,634,000Source | 20,685,000Source | 10,847,000Source | 3,185,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 15,616,000Source | 29,356,000Source | 38,634,000Source | 27,203,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 287,500,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -5,000Source | -53,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -7,685,000Source | 0Source | 0Source | -1,367,000Source |
| General and Administrative ExpenseUSD | 37,864,000Source | 43,498,000Source | 45,231,000Source | 40,515,000Source |
| Income Tax Expense (Benefit)USD | 718,000Source | 491,000Source | 523,000Source | 295,000Source |
| Net Income (Loss) Attributable to ParentUSD | -81,653,000Source | -127,976,000Source | -172,797,000Source | -162,956,000Source |
| Nonoperating Income (Expense)USD | 7,408,000Source | 9,761,000Source | 10,171,000Source | 3,291,000Source |
| Operating ExpensesUSD | 113,460,000Source | 151,939,000Source | 198,770,000Source | 178,852,000Source |
| Payments to Acquire InvestmentsUSD | 221,969,000Source | 156,584,000Source | 172,284,000Source | 261,154,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | 98,270,000Source | 66,524,000Source | 33,225,000Source | 96,059,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 119,476,000Source | 113,689,000Source | 130,376,000Source | 115,375,000Source |
| Cost of RevenueUSD | 72,722,000Source | 75,125,000Source | 101,376,000Source | 97,542,000Source |
| Operating Income (Loss)USD | -66,706,000Source | -113,375,000Source | -169,770,000Source | -161,019,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -80,935,000Source | -127,485,000Source | -172,274,000Source | -162,661,000Source |
| Income Tax Expense (Benefit)USD | 718,000Source | 491,000Source | 523,000Source | 295,000Source |
| Net Income (Loss) Attributable to ParentUSD | -81,653,000Source | -127,976,000Source | -172,797,000Source | -162,956,000Source |
| Earnings Per Share, BasicUSD per share | -5.37Source | -2.46Source | -3.48Source | -3.38Source |
| Earnings Per Share, DilutedUSD per share | -5.37Source | -2.46Source | -3.48Source | -3.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 15,211Source | 51,951Source | 49,588Source | 48,161Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 15,211Source | 51,951Source | 49,588Source | 48,161Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 4,300,000Source | 5,700,000Source | 5,800,000Source | 5,200,000Source |
| General and Administrative ExpenseUSD | 37,864,000Source | 43,498,000Source | 45,231,000Source | 40,515,000Source |
| Gross ProfitUSD | 46,754,000Source | 38,564,000Source | 29,000,000Source | 17,833,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -70,397,000Source | -116,693,000Source | -158,095,000Source | -153,226,000Source |
| Interest ExpenseUSD | 13,952,000Source | 23,871,000Source | 12,675,000Source | 3,566,000Source |
| Nonoperating Income (Expense)USD | 7,408,000Source | 9,761,000Source | 10,171,000Source | 3,291,000Source |
| Operating ExpensesUSD | 113,460,000Source | 151,939,000Source | 198,770,000Source | 178,852,000Source |
| Other General ExpenseUSD | 0Source | — | — | — |
| Research and Development ExpenseUSD | 21,235,000Source | 38,397,000Source | 57,307,000Source | 48,855,000Source |
| Selling and Marketing ExpenseUSD | 54,361,000Source | 70,044,000Source | 96,232,000Source | 89,482,000Source |
Filing attachments
om-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 om-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Outset Medical Reports Second Quarter 2026 Results San Jose, CA - August 6, 2026 - Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the second quarter ended June 30, 2026. Second Quarter and Recent Highlights • Net revenue totaled $31.6 million, an increase of 1% compared…
Read attachment ↗om-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 om-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Outset Medical Reports First-Quarter Results San Jose, CA - May 7, 2026 - Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights • Net revenue totaled $27.9 million, a decrease of 6% compared to $29.8 m…
Read attachment ↗om-ex99_1.htm · 8-K · 2026-02-11
EX-99.1 2 om-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results San Jose, CA - Feb. 11, 2026 - Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter, Year-End and Recent Highlights • Net revenue tot…
Read attachment ↗om-ex99_1.htm · 8-K · 2026-01-27
EX-99.1 2 om-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standards San Jose, CA - Jan. 27, 2026 - Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced 510(k) clearance by the U.S. …
Read attachment ↗om-ex99_1.htm · 8-K · 2026-01-12
EX-99.1 2 om-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Outset Medical Reports Unaudited Fourth Quarter and 2025 Results Appoints Medical Technology Veteran Karen N. Prange to Board of Directors San Jose, CA - Jan. 12, 2026 - Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. …
Read attachment ↗om-ex99_2.htm · 8-K · 2026-01-12
EX-99.2 3 om-ex99_2.htm EX-99.2 Outset Medical Investor Presentation 2026 Forward-looking statements and non-GAAP information This presentation and the accompanying oral statements contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “plan,” antici…
Read attachment ↗